美國Cell Therapeutics
Cell Therapeutic公司的arsenic trioxide(三氧化二砷)
美國FDA已批準Cell Therapeutic公司的癌癥治療劑三氧化二砷用于治療脊髓發育不良癥狀(MDS)的罕見藥品的指定。MDS也稱為前期的白血病或“不完全燃燒”的白血病,MDS是骨髓不能正常起作用以及產生的血細胞不足。該公司最近為三氧化二砷治療另一種罕見病復發的或難治的急性早幼粒細胞白血病申報了美國的新藥申請書,它對這種適應癥具有最快的跟蹤狀態,這種產品對治療多發性骨髓瘤具有罕見的藥品狀態
Cell Therapeutics, Inc., is a biopharmaceutical company focused on developing and commercializing novel agents that improve the safety and efficacy of existing standard-of-care chemotherapies, and those with unique,new mechanisms to kill cancer cells. We use genomic
information to determine which tumors have the greatest chance of responding favorably to a specific drug candidate.
This has the potential to change the way anticancer drugs are developed, by allowing investigators to pick the right drug for the right patient.